Filipa Lynce, MD

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Filipa Lynce, MD, discusses the current prognosis of patients diagnosed with inflammatory breast cancer subtypes.

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.

Filipa Lynce, MD, discusses the FDA approval of atezolizumab plus nab-paclitaxel for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1

Only by the end of my first year of fellowship did I realize that beyond your fellowship experience there is a lot you can gain.